Merck Stock News

Following is the unofficial transcript of a CNBC interview with Merck & Co., Inc. (NYSE:MRK) President & CEO Robert Davis on CNBCs TechCheck (M-F, 11AM-12PM ET) airing today, Monday, January 10th. Q4 2021 hedge fund letters, conferences and more Interview With Merck CEO Robert Davis MEG TIRRELL: Now joining us is the Merck CEO Rob []

Gilead Sciences (pembrolizumab) is partnering with Merck to examine a combination of the former''s Trodelvy with the latter''s Keytruda (pembrolizumab) for first-line NSCLC.

Merck (MRK) announced that its blockbuster therapy Keytruda met one of the dual primary endpoints in the KEYNOTE-091 trial, a first for the anti-PD-1 therapy in an adjuvant setting…

Neoleukin Therapeutics (NLTX) is trading ~2.4% higher in the pre-market after announcing a clinical trial collaboration and supply agreement with Merck (MRK).Per the terms, Neoleukin

This artificial intelligence-powered ETF ditched Netflix, Merck, and three other familiar stocks this month. Here''s what it bought.

Why Don''t We Cut Out The Middleman And Just Elect Pfizer & Merck? Authored by Charles Hugh Smith via OfTwoMinds blog, If we no longer have the capacity to distinguish between moral legitimacy and self-serving corruption, then we might as well eliminate the Middleman and vote directly for Pfizer or Merck. There''s a fancy word for cutting out the Middleman : disintermediation. Removing intermediaries who take a cut but neither produce nor add value makes perfect sense, reducing costs and increasing efficiency. Maybe it''s time to eliminate the politicians who soak up hundreds of millions of dollars in campaign contributions from corporations and the super-wealthy and just elect Pfizer, Merck, Amazon, General Dynamics, etc. directly. Since corporate lobbyists write most of the legislation anyway, why not cut out the intermediaries in the process? The super-wealthy buy political power via Political Action Committees (PACs and Super-PACs), think tanks and philanthro-capitalist foundations (Gates Foundation, et al.).

Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK).

Shares of Absci Corp. skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to $610 million in upfront fees and milestone payments from Merck & Co. Inc. as part of a research collaboration agreement. Trading volume ballooned to 9.7 million shares, compared with the full-day average of about 324,800 shares, to make the stock the biggest gainer and most actively traded ahead of the open. Under the collaboration, Absci''s Bionic Protein amino acid technology will be used to produce enzymes tailored to Merck''s biomanufacturing platform. Merck also has the option to nominate up to three targets and enter into a drug discovery collaboration agreement. The stock, which closed at a record low of $6.14 on Thursday, had tumbled 42.9% over the past three months through Thursday, while the iShares Biotechnology ETF has shed 8.8% and the S&P 500 has gained 6.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

Futures Rise Ahead Of Jobs Data That Could "Wreak Havoc In Markets" US index futures climbed on Friday, paring this weeks losses fractionally as investors braced for jobs data that should provide clues about the pace of Fed tightening and which is expected to come in strong (whisper number at 502k, above 447k estimate, up from 210K last month; Wednesdays ADP print was 807k, well above 410k estimate, our full preview is here ) but not too strong - remember we now live in a "good news is bad news" world - or else the market will freak out that the Fed will hike even faster than is currently expected. Nasdaq futures also showed signs of recovery after a three-day selloff even as cryptocurrencies crashed again during the Asian session. As of 730am, emini S&P futures were up 4 points or 0.1%, Nasdaq futures were 0.24% higher, or 37 points and Dow futures were unchanged.Treasuries were steady, with the two-year yield heading for the biggest weekly spike since October 2019. Crude oil headed for the longest streak of weekly gains since October on tightening supplies.

Absci (ABSI) soars 43.5% premarket after entering into a research collaboration with Merck (MRK)

Merck is seeking to capitalize on the success of mRNA vaccines, the technology behind the Covid-19 inoculations.

India Won''t Add Merck''s COVID-19 Pill To National Treatment Protocol, Citing Safety Concerns Authored by Katabella Roberts via The Epoch Times, India s top health research body announced on Wednesday that it wont be adding Mercks COVID-19 antiviral pill molnupiravir to its national treatment protocol, citing concerns over its safety. The state-run Indian Council of Medical Research (ICMR) said it had become aware of major safety concerns that prompted the decision, despite Indias drug regulator in December approving the drug for emergency use. It comes after France in December also canceled its order for the drug , developed by Merck and Ridgeback Biotherapeutics, following disappointing trial data suggesting its drug was markedly less effective than previously thought. Molnupiravir has major safety concerns including teratogenicity, mutagenicity, muscle and bone damage. If this drug is given, contraception must be done for three months as the child may have problems, ICMR Director-General Balram Bhargava told local media on Wednesday.

While the drug regulator last week approved Mercks molnupiravir for emergency use, the director general of Indian Council of Medical Research said the drug has major safety concerns.The FDA cautioned that Mercks drug isnt recommended for use by those who are pregnant

Aurobindo Pharma launches Covid-19 drug Molnupiravir in India.Earlier this week, the pharmaceutical major Dr Reddy''s Laboratories Ltd said it will soon launch the generic version of Merck''s antiviral Covid-19 pill, Molnupiravir